Comparison of pharmacokinetics, pharmacodynamics, safety, and immunogenicity of a candidate biosimilar INTP23.1 with EU and US‑approved denosumab reference products in healthy adult men

Puntos clave

• Safety profiles of INTP23.1 show comparable results to reference denosumab products, supporting its potential use.
• Pharmacokinetics and pharmacodynamics assessments reveal similar efficacy between the biosimilar and reference products.
• Analysis focuses on healthy adult men, providing critical data for future clinical applications of biosimilars.
• Immunogenicity results contribute valuable insights into long-term treatment safety of biosimilar INTP23.1.